10/1/2024 | For immediate release | Contact: Kate O’Neill ([email protected]) Investment in Alzheimer’s Research Today Will Yield Health Benefits for
Project will empower advocates, enhance research for people at high risk of Alzheimer’s disease who have Down syndrome Washington, D.C.
Information revealed at the 2024 AAIC conference on the ACTC-DS-led study in DS-associated Alzheimer’s disease with Lilly’s anti-amyloid drug Kisunla.
FDA issues approval for Kisunla, new Alzheimer’s drug; Down syndrome community optimistic On Tuesday, July 2, the U.S. Food and
Major pharmaceutical company announces Down syndrome population will see a clinical trial of new Alzheimer’s drug People with Down syndrome
James Lind, a United Kingdom’s Royal Navy surgeon, is considered the “Father of Clinical Trials.” Each year, on May 20,
LuMind IDSC is encouraged by today’s news that the U.S. Food and Drug Administration (FDA) is requesting more time and
“I want to enjoy my life for a long time. I want to grow old just like everyone else.” These
Thanks to the extraordinary support and engagement of the Down syndrome community, LuMind IDSC is celebrating a year of outstanding
This video discusses why, how, and when families should consider participating in Down syndrome research. Source: Massachusetts Down Syndrome Congress
